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Abstract 
Traumatic neuroma is neuronal tissue proliferation developed in a nerve injury site, often associated with increased 
sensitivity and spontaneous or evoked neuropathic pain. The mechanisms leading to the disorganized nerve 
proliferation are not completely understood, though inflammation in the injured nerve vicinity most likely has a role in 
the process. Inflammatory cytokines are also known to be involved in the maintenance and development of post-
traumatic and neuropathic pain. The goal of this study was to quantify and compare pro and anti-inflammatory 
cytokines (TNF-α, IL-1β, IL-6 and IL-10) levels in nerves that formed neuromas and nerves that did not, following 
sciatic nerve transection. 
A total of 30 rats were used in this study. Twenty rats underwent sciatic nerve transection and 10 underwent sham 
surgery. Six weeks post-surgery nerve sections were collected and histologically evaluated for neuroma formation. 
The samples were then classified as neuroma, non-neuroma and sham groups. TNF-α, IL-1β, IL-6 and IL-10 levels 
were measured in the nerves employing ELISA. TNF-α levels were significantly higher in both neuroma and non-
neuroma-forming injured nerves compared to the sham group. IL-1β and IL-6 levels were significantly higher in the 
neuroma-forming nerves compared to the sham group. IL-10 levels were significantly higher in the non-neuroma 
group compared to the sham group. In conclusion IL-6, and IL-1 β may have a role in the formation of traumatic 
neuroma while IL-10 may inhibit neuroma formation. 
 
Introduction 
The exact prevalence of neuromas following nerve injury is not known, though it has 
been variously reported as 10% to as high as 80% [1, 2]. Neuromas may occur following various 
injuries to the nerve, such as pressure, inflammation, ischemia, stretching, partial laceration, or 
complete transection [3].  Neuroma formation usually occurs during the nerve’s attempt at self-
repair [4]. Histologically, neuromas consist of irregularly interwoven bundles of axons, Schwann 
cells, fibroblasts and their collagen products [5]. Up-regulation of sodium channels and a 
decrease in their thresholds may partly explain spontaneous activity, hyperalgesia, and easily-
evoked activity. This can result in the development of hyperalgesia, allodynia, and spontaneous 
pain [6, 7]. While inflammation clearly plays an important role in the process of nerve injury and 
repair, the role of inflammatory mediators such as cytokines in neuroma formation, if any, is 
unclear [8].  
The management of neuromas may be challenging. Various modalities, such as surgery, 
nerve blocks, botox, and local and systemic medications have been used, often with limited 
success [9-13]. When detectable visibly or by palpation, neuromas can be surgically removed or 
reduced in size by electrocoagulation or freezing [4, 14]. In other cases the neuroma can be 
rerouted into bone or muscle [15-18]. However, the current treatment options are often 
ineffective, and also have the potential to increase pain [14]. 
One reason for this limited treatment effectiveness has been an incomplete understanding 
of the underlying mechanisms of neuroma formation. What is known is that in the period 
immediately following nerve damage, an inflammatory reaction takes place, which can have a 
significant role in neuroma development.  The initial inflammatory process typically involves the 
accumulation of numerous bioactive molecules such as bradykinin, nerve growth factor, 
serotonin, and prostaglandins. This can sensitize peripheral receptors, which can present as 
hyperalgesia and allodynia [19, 20]. Ectopic discharge and hyper-excitability have also been 
shown to occur in neuroma axons via up-regulation of sodium and calcium channels and down-
regulation of potassium channels [21-23]. Nerve injury may be followed by degeneration of the 
affected C-fibers.  A-beta fibers that typically do not transmit noxious information may undergo 
phenotypical changes to do so. Persistent nociceptive input from the neuroma site can eventually 
result in central sensitization, which can involve the activation of glial cells, sensitization of wide 
dynamic range neurons, and glutamate-induced excitotoxicity of inhibitory interneurons. 
Pro inflammatory cytokines such as IL-1β, 1L-6 and TNF-α are elevated in various 
neuropathic pain conditions [24-30].  Inflammatory cells have been shown to be present in 
traumatic neuromas. TNF-α and IL-1β appear to disturb the regeneration of injured nerves [8, 
31]. Anti-inflammatory cytokines like IL-10 have the potential to reduce neuropathic pain by the 
down-regulation of pro-inflammatory cytokines such as TNF-α, IL-1 β and IL-6 [32, 33]. In the 
central nervous system, the production of these key cytokines and glial cells plays a critical role 
in the processing of abnormal pain signaling [34, 35]. These cytokines have been studied 
extensively in nerve damage, inflammation and the pain associated with it. As the pathogenesis 
of neuromas often includes nerve damage, the cytokine profile may be the same for both these 
conditions. 
The goal of this study was to quantify TNF-α, IL-1β, IL-6 and IL-10 levels in sciatic 
nerves six weeks following complete transection, and to compare their levels in nerves that did 
or did not develop neuromas. We hypothesized that pro-inflammatory cytokines (TNF-α, IL-1β, 
IL-6) levels would be higher in nerves that developed neuroma, while anti-inflammatory 
cytokines (IL-10) level will be lower in the same nerves [36]. 
Methods 
All procedures and experimental protocols were approved by the Institutional Animal Care and 
Use Committee at Rutgers, Newark, NJ (10077). Experiments were in accordance with the 
National Institute of Health regulations, and the guidelines of the International Association for 
the Study of Pain [37]. 
Animals 
Male adult Sprague-Dawley rats were ordered from a single lab (Charles laboratory). 
Rats weighed 300-325g at the time of surgery and were housed in the animal facility under 
veterinary supervision. Rats were allowed standard rodent chow and reverse osmotically-treated 
water ad libitum, and maintained on a twelve-hour day and night cycle.  
Ten of the rats underwent sham surgery, and 20 rats underwent sciatic nerve transection. 
The sham-treated rats served as controls. Six weeks following the transection, the rats were 
euthanized. The transected nerves were evaluated histologically by a pathologist and categorized 
into neuroma and non-neuroma formation groups. 
Surgery  
For surgical procedures, rats were anaesthetized with a ketamine (50 mg/kg) and xylazine (7.5 
mg/kg) solution administered intraperitoneally. The surgical site was shaved using a trimmer and 
sterilized with betadine and alcohol prior to the procedure. The eyes were lubricated and the rats 
were placed on a warming pad to maintain consistency of body temperature during surgery. A 
single, trained investigator performed the surgeries.  
 
a. Sciatic Nerve Transection 
The left common sciatic nerve was exposed via a mid-thigh incision proximal to the 
sciatic trifurcation, and transection was performed. Nerve tissue measuring approximately 1cm 
was removed distal to the incision. The incision was closed with stainless steel clips [38]  
b. Sham Surgery 
The common sciatic nerves were exposed at the mid-thigh level by blunt dissection 
through the biceps femoris, and gently separated from adjacent tissue. The incision was closed 
with stainless steel clips. The purpose of the sham surgery group was to control for the 
possibility that exposure of the nerve could cause the secretion of cytokines. 
Histology and Neuroma evaluation 
For the histological examinations, the tissue was immediately fixed using Zamboni’s Fixative at 
4oC for 24 hours, after which time the tissue was processed and embedded in paraffin. 
Transverse sections (4µm) were cut from the proximal ends of the transected nerves, and also 
from the sham operated nerves. The sections were stained with hematoxylin & eosin (H&E) [8]. 
 On gross examination, traumatic neuromas appeared as firm, white-gray nodules which 
were located in continuity with the proximal end of the injured or transected nerve. 
Histologically under intermediate power microscopy, traumatic neuromas showed extensive 
collagenization of the nerve tissue with residual chronic inflammation. Under higher power, 
histology revealed scarring and separation of collagen bundles and nerve fibers. The key finding 
in the histologic diagnosis of traumatic neuroma was the more extensive fibrosis, compared to 
that found in non-neuroma group (Figures 1 and 2) 
Enzyme-Linked Immunosorbent Assay (ELISA) 
Tissue samples were weighed, homogenized and centrifuged followed by collection of 
the medium. The medium and standards were pipetted and assayed with a site enzyme-linked 
immunoassay (ELISA, R&D Systems Inc., MN, USA) for IL-10, TNF-α, IL-1β and IL-6. After 
the binding of the primary and secondary antibodies, the substrate and stop solutions were 
applied, which changed the color of the bound substance. The intensity of the color reflected the 
amount of the cytokine bound. Using a curve plotted from standard solutions, cytokine levels 
were calculated as: pg. (cytokine)/ mL (medium)/mg (tissue) [33] 
Data Analysis 
Statistical tests were performed two-tailed, and the significance level was set to alpha 0.05. 
Data were tabulated and analyzed using JMP statistical analysis software (JMP, Version 10. SAS 
Institute Inc.). Mean values and standard deviations (SDs) were calculated for all continuous 
variables examined. All means were arithmetic means unless otherwise specified. Descriptive 
statistics are presented in the graphs as means and standard errors of the means. 
In the neuroma, non-neuroma and sham group, data were collected for left sciatic nerve six 
weeks following the surgical procedures. ANOVA (RMANOVA), followed by Tukey’s method 
for post-hoc analysis, was used to detect differences in cytokine changes.  
Results 
 Results are expressed as cytokine levels measured in the surgically operated nerve for 
neuroma, non-neuroma and sham groups (pg/mL/mg ± S.D).  
TNF α levels were significantly increased in both the neuroma (23.46 ± 1.4 pg/mL/mg) 
and the non-neuroma groups (17.942 ± 1.818 pg/mL/mg), compared to the sham group (1.26 ± 
0.14 pg/mL/mg).  The TNF α levels were also significantly higher in the neuroma group 
compared to the non-neuroma group (P < 0.0001) (Figure 3). 
 IL-6 levels were significantly increased in both the neuroma group (3,426.4 ± 237.6 
pg/mL/mg) and the non-neuroma groups (703.470 ± 78.6 pg/mL/mg), compared to the sham 
groups (23.4 ±2.1 pg/mL/mg). IL-6 levels were also significantly higher in the neuroma group 
compared to the non-neuroma group (P < 0.0001) (Figure 4) 
 IL-1β levels were significantly elevated in the neuroma group (509.2 ± 118.5 pg/mL/mg, 
p<0.05) compared to both the non-neuroma (49.4 ± 9.6 pg/mL/mg) and sham group (17.9± 1.82 
pg/mL/mg).  There was no significant difference in IL-1β levels between the non-neuroma and 
sham groups (49.4 ± 9.6 pg/mL/mg and 17.9± 1.82 pg/mL/mg, p>0.05 respectively) (Figure 5). 
 IL-10 levels were significantly elevated in the non-neuroma group (338.9± 58.3 
pg/mL/mg, p<0.01) compared to the neuroma group (179.5 ± 19.7 pg/mL/mg). No difference 
was found between the sham (222.2± 48.3 pg/mL/mg) and neuroma group (179.5 ± 19.7 
pg/mL/mg, p>0.05) (Figure 6). 
 
 
 
Discussion 
 The most noteworthy findings of this study were (1) all three pro inflammatory cytokines 
evaluated in this study were elevated in the neuroma group compared to the non- neuroma and 
sham groups, (2) IL-1β increase, relative to the sham group, was exclusive to the neuroma-
formation group, and (3) TNF-α and IL-6 were increased in both the neuroma and non- neuroma 
groups. The levels for the anti-inflammatory cytokine evaluated in this study, IL-10, were 
significantly higher in the non-neuroma group. 
TNF-α is produced by activated macrophages and other cells such as T and B 
lymphocytes, Natural Killer cells, lymphokine activated cells, astrocytes, endothelial cells or 
smooth muscle cells [39]. TNF-α levels are elevated in inflammatory conditions and its presence 
can indicate an ongoing inflammatory process. It also appears to be a key player at both central 
and peripheral nerve degenerative pathologies, and in maintenance of neuropathic pain after 
following nerve injury [40]. In this study, as was expected, it was elevated in both neuroma and 
non-neuroma nerves that underwent transection.  
IL-6 and IL-1β levels were significantly elevated only in the neuroma-forming nerves. IL-1β 
is a pro inflammatory cytokine, produced primarily by monocytes and macrophages, as well as 
by astrocytes, oligodendrocytes, Schwann cells, T cells, fibroblasts and other cells [41]. IL-1β, is 
involved in the immune response and signal transduction both in the peripheral and the central 
nervous systems.   It plays an important role in inducing and maintaining neuropathic pain. 
Moreover, peripheral or central administration of IL-1β is usually followed by hyperalgesia [27, 
42]. The pain accompanying neuromas may be associated to the increased IL-1β levels. 
Treatment with neutralizing antibodies to IL-1 receptor type I have been shown to reduce the 
development of neuropathic pain [28]. One reason for elevated IL-1β levels in the neuroma group 
in this study could have been increased neural activity in that group.  Ectopic firing of sensitized 
nociceptive neurons, and the increased density of nociceptors nerve sprouts, may increase 
quantities and secretion of IL-1β.  Studies have also reported IL-1 to attenuate neuropathic pain 
and an increase in IL-1 levels in neuromas, while this study found an increase in IL-1β in 
neuromas [8, 43]. 
IL-6 is a multifunctional cytokine, with pro inflammatory and regulatory effects, and is  
induced during acute inflammation associated with injury, infection and neuronal death.  IL-6 
levels were significantly increased in both neuroma and non-neuroma nerves compared to the 
sham group, but the neuroma-forming nerves had significantly higher levels compared to the 
non-neuroma group.  This may also be for the same reasons previously mentioned. Human 
studies in acoustic neuromas have also shown an association with elevated IL-6 levels [44]. 
IL-10 was only increased in the non-neuroma group and may suggest a protective effect. IL-
10 is an anti-inflammatory cytokine produced by a wide variety of adaptive and innate immune 
cells such as CD4 and CD 8 T-lymphocytes, dendritic cells mast cells, natural killer cells, 
eosinophils macrophages and non-hematopoietic cells (35-36). IL-10 is considered primarily to 
have an anti-inflammatory effect and does so by suppressing the production of inflammatory 
cytokines [45, 46]. Recent studies have shown that IL-10 may also reduce neuropathic pain.  
Moreover, the efficacy of certain neuropathic pain medications is in part associated with IL-10 
[33, 47]. Other studies have demonstrated an upregulation of IL-10 in response to nerve injury 
[48]. Future studies focusing on the administration of IL-10 and neuroma formation should be 
explored.  
One limitation of this study was our lack pain behavior data.  This absence was due to the 
fact that the nerve supplying the target organ (paw) was severed completely.  Further studies 
could be done to evaluate the pain behavior using the neuroma-in-continuity model, and correlate 
the same with the quantity of cytokines. Another method that could be considered is 
electrophysiology studies to measure neural activity as a marker for the presence of a neuroma 
[49]. Knowledge of the precise agents involved in traumatic neuromas will help in understanding 
the underlying mechanisms in neuroma formation and the development of treatment.  Further 
studies should explore neuroma formation and cytokines in the injured nerve vicinity followed 
by medication efficacy and safety studies. Animal models of neuroma formation can help 
increase our understanding of these underlying mechanisms, and possibly lead to enhanced 
treatment in future. In summary TNF- α, IL-6, and IL-1 β may play a strong role in the formation 
of traumatic neuromas, while IL-10 may serve a protective function. 
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